Oncotarget

Research Papers:

The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts

Leonid Visochek, Dikla Atias, Itay Spektor, Asher Castiel, Talia Golan and Malka Cohen-Armon _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2019; 10:6269-6282. https://doi.org/10.18632/oncotarget.27268

Metrics: PDF 889 views  |   HTML 3982 views  |   ?  


Abstract

Leonid Visochek1, Dikla Atias3, Itay Spektor3, Asher Castiel3, Talia Golan1,3 and Malka Cohen-Armon1,2

1 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel

2 Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv 69978, Israel

3 Oncology Institute, Sheba Medical Center, Ramat Gan 53621, Israel

Correspondence to:

Malka Cohen-Armon,email: marmon@tauex.tau.ac.il

Keywords: PJ34; pancreas cancer; stroma; PANC1 cancer xenografts

Received: May 21, 2019     Accepted: September 10, 2019     Published: October 22, 2019

ABSTRACT

Recent reports demonstrate an exclusive eradication of a variety of human cancer cells by the modified phenanthridine PJ34. Their eradication during mitosis is attributed to PJ34 preventing NuMA clustering in the mitotic spindle poles of human malignant cells, which is crucial for their normal mitosis. Here, the effect of PJ34 is tested in cell cultures and xenografts of human pancreas ductal adenocarcinoma. Evidence is presented for a substantial reduction (80–90%) of PANC1 cancer cells in xenografts, measured 30 days after the treatment with PJ34 has been terminated. Benign cells infiltrated into the PANC1 tumors (stroma) were not affected. Growth, weight gain and behavior of the treated nude mice were not impaired during, and 30 days after the treatment with PJ34. The efficient eradication of malignant cells in human pancreas cancer xenografts presents a new model of pancreas cancer treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27268